Concert Pharmaceuticals Stock Price To Earning
| CNCEDelisted Stock | USD 8.37 0.01 0.12% |
Concert Pharmaceuticals fundamentals help investors to digest information that contributes to Concert Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Concert Stock. The fundamental analysis module provides a way to measure Concert Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Concert Pharmaceuticals stock.
Concert |
Concert Pharmaceuticals Company Price To Earning Analysis
Concert Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Concert Pharmaceuticals Price To Earning | 3.08 X |
Most of Concert Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Concert Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Concert Pharmaceuticals has a Price To Earning of 3.08 times. This is 88.08% lower than that of the Biotechnology sector and 37.53% lower than that of the Health Care industry. The price to earning for all United States stocks is 89.28% higher than that of the company.
Concert Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Concert Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Concert Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Concert Pharmaceuticals by comparing valuation metrics of similar companies.Concert Pharmaceuticals is currently under evaluation in price to earning category among its peers.
Concert Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 86.63 M | |||
| Shares Outstanding | 48.02 M | |||
| Shares Owned By Insiders | 3.77 % | |||
| Shares Owned By Institutions | 77.05 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | 3.08 X | |||
| Price To Book | 1.67 X | |||
| Price To Sales | 7.05 X | |||
| Revenue | 32.58 K | |||
| Gross Profit | (54.98 M) | |||
| EBITDA | 1.4 M | |||
| Net Income | (80.05 K) | |||
| Cash And Equivalents | 154.57 M | |||
| Cash Per Share | 3.22 X | |||
| Total Debt | 14.51 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 10.03 X | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | (55.15 M) | |||
| Short Ratio | 0.26 X | |||
| Earnings Per Share | (3.17) X | |||
| Target Price | 11.67 | |||
| Number Of Employees | 64 | |||
| Beta | 0.49 | |||
| Market Capitalization | 401.95 M | |||
| Total Asset | 165.32 M | |||
| Retained Earnings | (210.05 M) | |||
| Working Capital | 137.48 M | |||
| Current Asset | 144.11 M | |||
| Current Liabilities | 6.63 M | |||
| Z Score | 14.8 | |||
| Net Asset | 165.32 M |
About Concert Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Concert Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Concert Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Concert Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Concert Stock
If you are still planning to invest in Concert Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Concert Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |